(RTTNews) - Glenmark Pharmaceuticals Inc., USA (GLENMARK.NS), Thursday announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules.

Glenmark Pharmaceuticals on Tuesday, January 21, said its US arm has launched Phytonadione Injectable Emulsion USP, 10mg/ml ...

The scalable platform can be initially deployed, and later upgraded to include Hospira MedNet™ safety software to meet your evolving patient care needs. The unique, innovative PlumSet ...

In May, the lower court sided with Hospira and ruled that three patents Astellas is relying on for Lexiscan market exclusivity in the US – 8,106,183; 8, 524,883; and RE47301 – are not ...

Glenmark Pharmaceuticals has launched Phytonadione injectable emulsion through its US arm, targeting anticoagulant markets.

The first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), has been launched in major European markets by Hospira. The treatment received a positive opinion from the European ...

It further said that the single-dose ampules are both bioequivalent and therapeutically equivalent to the reference listed ...

Glenmark launches phytonadione injectable emulsion USP, 10 mg/mL single dose ampules: Our Bureau, Mumbai Tuesday, January 21, 2025, 12:15 Hrs [IST] Glenmark Pharmaceuticals Inc., ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules.

The single-dose ampules is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 Injectable Emulsion USP, 10 mg/mL of Hospira, Inc, the statement added.

According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market 2 achieved annual sales of approximately $19.7 million*.